Tyme Technologies Inc. (TYME) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for TYME in the last 30 days. The most recent was published Sep 30, 2022.
Latest news
25 items- SECSEC Form 15-12G filed by Tyme Technologies Inc.15-12G - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form EFFECT filed by Tyme Technologies Inc.EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form EFFECT filed by Tyme Technologies Inc.EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- INSIDERSEC Form 4: Sokol Gerald H returned 5,865 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Porfido Frank L. returned 10,000 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Hoffman Steve returned 20,022,566 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Michels Douglas A returned 110,000 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Biehl James returned 105,150 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4 filed by Eckard Jonathan4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Galaini Barbara returned 258,300 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Tyson Timothy returned 5,865 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4: Carberry David returned 100,000 shares to the company, closing all direct ownership in the company4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4 filed by Baker Christine D.4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4 filed by Cunningham, Richard Anthony4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- INSIDERSEC Form 4 filed by Degolyer Donald W4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
- SECSEC Form S-8 POS filed by Tyme Technologies Inc.S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form S-8 POS filed by Tyme Technologies Inc.S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form S-8 POS filed by Tyme Technologies Inc.S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form S-8 POS filed by Tyme Technologies Inc.S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form POS AM filed by Tyme Technologies Inc.POS AM - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form S-8 POS filed by Tyme Technologies Inc.S-8 POS - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form POS AM filed by Tyme Technologies Inc.POS AM - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- 13D/GSEC Form SC 13G/A filed by Tyme Technologies Inc. (Amendment)SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
- SECTyme Technologies Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
- SECSEC Form 25-NSE filed by Tyme Technologies Inc.25-NSE - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
TYME FAQ
6 questionsWhat does Tyme Technologies Inc. do?
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has...What is the latest news on TYME?
Quantisnow has not tracked any new filings, ratings or press releases for TYME in the last 30 days. The most recent wire item was published on September 30, 2022.Where does TYME stock trade?
Tyme Technologies Inc. (TYME) is listed on NASDAQ.What sector and industry is TYME in?
Tyme Technologies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to TYME?
Notable peers in the same industry include MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare TYME side-by-side with any of them on Quantisnow.How can I track TYME on Quantisnow?
Quantisnow aggregates Tyme Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TYME to receive live email and push alerts on every new disclosure.